Quick Answer
Arcturus Therapeutics Holdings Inc. reported Operating Income Loss of -$76.26 million for the year ending 2025.
- Arcturus Therapeutics Holdings Inc. showed an increase of +20.3% in Operating Income Loss from 2024 to 2025.
- This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$10.07 million | Q3 2018: -$4.36 million | Q1 2019: -$6.51 million | Q2 2019: -$572.0 thousand | Q3 2019: -$7.62 million | Q4 2019: -$10.82 million | Q1 2020: -$9.46 million | Q2 2020: -$10.04 million | Q3 2020: -$20.94 million | Q4 2020: -$31.08 million | Q1 2021: -$57.67 million | Q2 2021: -$53.72 million | Q3 2021: -$53.82 million | Q4 2021: -$37.65 million | Q1 2022: -$50.38 million | Q2 2022: -$22.09 million | Q3 2022: -$36.81 million | Q1 2023: $14.76 million | Q2 2023: -$55.37 million | Q3 2023: -$19.31 million | Q1 2024: -$30.41 million | Q2 2024: -$21.13 million | Q3 2024: -$10.74 million | Q1 2025: -$16.83 million | Q2 2025: -$11.62 million | Q3 2025: -$16.51 million.
- Over the full 8 years of available data (2018 to 2025), Arcturus Therapeutics Holdings Inc.'s Operating Income Loss has declined by 249.6%.
- Historical annual values: Fiscal year 2025: -$76.26 million | Fiscal year 2024: -$95.67 million | Fiscal year 2023: -$78.21 million | Fiscal year 2022: $12.18 million | Fiscal year 2021: -$202.85 million | Fiscal year 2020: -$71.52 million | Fiscal year 2019: -$25.51 million | Fiscal year 2018: -$21.81 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: